KemPharm registers $62.69 million stock for sale of 3 million shares

Cowen, RBC Capital, Canaccord Genuity and Oppenheimer assist with sale

By Devika Patel

Knoxville, Tenn., Dec. 18 – KemPharm, Inc. will sell 3 million common shares in a public offering with a 30-day greenshoe of 450,000 additional shares, according to a Form S-1 filed Friday with the Securities and Exchange Commission. The company has registered up to $62,686,500 of stock.

Cowen and Co. and RBC Capital Markets are the bookrunning managers. Canaccord Genuity and Oppenheimer & Co. are the co-managers.

Proceeds will be used for clinical trials, research and development, working capital and other general corporate purposes.

The clinical-stage specialty pharmaceutical company is based in Coralville, Iowa.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.